Clinical trials: Metastatic Solid Tumor
Advanced Solid Tumor
A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor
The reason for this study is to see if the CD73 inhibitor HLX23 alone is safe and effective in participants with advanced solid cancer.
- Trial name
- NCT04797468
- Testing
- HLX23
- Where
- 6 sites in United States
- Sponsor
- Shanghai Henlius Biotech
Gastric Cancer, Colon Cancer
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Gastric Cancer, Colon Cancer, Pancreas Cancer, Esophagus Cancer
- Trial name
- NCT06010862
- Testing
- CEA CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Solid Tumor
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875
This is the first-in-human study with SYD1875, an antibody-drug conjugate (ADC) comprising of a humanized IgG1 monoclonal antibody directed against the 5T4 oncofetal antigen covalently conjugated to a duocarmycin-based…
- Trial name
- NCT04202705
- Testing
- SYD1875
- Where
- 3 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Byondis B.V.
Advanced or Metastatic Solid Tumors
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung…
- Trial name
- NCT01928394
- Testing
- Nivolumab, Ipilimumab, Cobimetinib
- Where
- 38 sites in United States, Canada and 6 more
- Volunteers
- 1,163 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Solid Tumor
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated…
- Trial name
- NCT05039931
- Testing
- GNC-035
- Where
- China
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumors
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced solid tumors. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and…
- Trial name
- NCT01302405
- Testing
- PRI-724
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Prism Pharma Co., Ltd.
Solid Tumors
Study of INCB123667 in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with…
- Trial name
- NCT05238922
- Testing
- INCB0123667, Palbociclib, Bevacizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 291 people
- Sponsor
- Incyte Corporation
Advanced Solid Tumors
Phase 1 Study of OSI-930 in Cancer Patients
Open label, phase 1, dose escalation
- Trial name
- NCT00513851
- Testing
- OSI-930
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Advanced and/or Metastatic Solid Tumours
A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
CB307 is a trispecific Humabody® targeting CD137; PSMA; and human serum albumin (HSA) undergoing Phase 1 assessment in patients with PSMA+ solid tumours.
- Trial name
- NCT05836623
- Testing
- Radiolabelled CB307, CB307
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Crescendo Biologics Ltd.
Malignant Neoplasm
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors. The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.
- Trial name
- NCT07600749
- Testing
- MK-4884
- Where
- 10 sites in United States, Canada and 3 more
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced or Metastatic Solid Tumors
Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid Tumors
This research design for center, increasing openness, dose and dose extension phase I clinical trials, research the main evaluation BAT6005 injection single drug in patients with advanced malignant solid tumors in the safety…
- Trial name
- NCT05116709
- Testing
- BAT6005 injection
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Bio-Thera Solutions
Neoplasms, Breast Neoplasms
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
This is a study in adult patients with different types of cancer. The purpose of this study is to find a safe dose of: Xentuzumab in combination with abemaciclib Xentuzumab in combination with abemaciclib and hormonal therapies…
- Trial name
- NCT03099174
- Testing
- Xentuzumab, Abemaciclib, Letrozole
- Where
- 30 sites in United States, Denmark and 5 more
- Volunteers
- 133 people
- Sponsor
- Boehringer Ingelheim
SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors.
- Conditions
- SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
- Trial name
- BRAVESST2 (NCT07129252)
- Testing
- CRN09682
- Where
- 27 sites in United States, Spain
- Volunteers
- 150 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Metastatic Colorectal Cancer
Sym004 in Patients With Advanced Solid Tumors
This trial is designed as a multi-centre, open label, dose-escalation, phase I trial and consists of five parts.
- Trial name
- NCT01117428
- Testing
- Sym004
- Where
- 7 sites in United States, Belgium and 1 more
- Volunteers
- 111 people
- Sponsor
- Symphogen A/S
Solid Tumors, KRAS Mutation
A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)
This study is open to Japanese adults with different types of advanced cancer that are positive for NRAS/KRAS mutations. This is a study in people for whom previous treatment was not successful or no standard treatment exists.
- Trial name
- NCT04742556
- Testing
- BI 3011441
- Where
- 3 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Advanced Malignant Tumor
QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors
In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with…
- Trial name
- NCT04326829
- Testing
- QL1604
- Where
- 2 sites in China
- Volunteers
- 86 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Advanced Malignancy, Advanced Solid Tumors
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis
- Trial name
- SDX-0101 (NCT02743637)
- Testing
- SDX-7320
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- SynDevRx, Inc.
Specific Advanced Solid Tumors
Study of ACR-2316 in Specific Advanced Solid Tumors
This is a first in-human, Open-label Phase 1/2 study to assess the safety and activity of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
- Trial name
- NCT06667141
- Testing
- ACR-2316
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Acrivon Therapeutics
Solid Malignancies
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
The goal of this clinical trial is to test in Chinese Subjects with Metastatic or Recurrent Solid Malignancies. The main questions it aims to answer are: How is the PK of tisotumab vedotin? How is the immunogenicity of tisotumab…
- Trial name
- NCT05866354
- Testing
- Tisotumab Vedotin
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.